Treatment of Aspergillus fumigatus Pneumonia

First-Line Treatment Options

The American College of Physicians recommends voriconazole as the first-line treatment for Aspergillus fumigatus pneumonia, with a loading dose of 6 mg/kg IV every 12 hours for the first 24 hours, followed by a maintenance dose of 4 mg/kg IV every 12 hours for at least 7 days, due to its superior efficacy compared to amphotericin B, with significantly better survival rates (71% vs 58% at 12 weeks) and successful outcomes (53% vs 32%) 1
Therapeutic drug monitoring is recommended for voriconazole to ensure adequate drug levels and minimize toxicity, with a strength of evidence level of high 3

The Infectious Diseases Society of America recommends liposomal amphotericin B at 3-5 mg/kg/day IV as an alternative first-line therapy in patients who cannot tolerate voriconazole or have contraindications, with a strength of evidence level of moderate 2
Isavuconazole is another alternative first-line agent with comparable efficacy to voriconazole, with a strength of evidence level of high 4

In areas or institutions with high prevalence of azole-resistant A. fumigatus, liposomal amphotericin B may replace voriconazole as first-line treatment, with a strength of evidence level of high 5
For A. fumigatus with voriconazole MIC >2 mg/L (resistant), liposomal amphotericin B therapy is recommended, with a strength of evidence level of high 3

The Pediatric Infectious Diseases Society recommends voriconazole as first-line agent for invasive aspergillosis in all children except neonates, with a strength of evidence level of high 5
For neonates, liposomal amphotericin B is the first choice, with a strength of evidence level of moderate 5

Serial clinical evaluation of symptoms and signs, regular radiographic imaging with CT, and serial serum galactomannan assays should be used to monitor response to treatment, with a strength of evidence level of high 2
Progressive increase in Aspergillus antigen levels over time signifies a poor prognosis, with a strength of evidence level of moderate 2

Delaying antifungal therapy while awaiting diagnostic confirmation can worsen outcomes in high-risk patients, with a strength of evidence level of high 4
Using echinocandins as primary monotherapy is not recommended due to inferior efficacy compared to voriconazole, with a strength of evidence level of high 4
Failing to monitor drug levels for azole antifungals can lead to suboptimal treatment outcomes or toxicity, with a strength of evidence level of high 4
Misinterpreting radiological progression shortly after treatment initiation or following neutrophil recovery as treatment failure, with a strength of evidence level of moderate 5